Abstract-Vascular remodeling, rather than vasoconstriction, is believed to account for high vascular resistance in severe pulmonary arterial hypertension (PAH). We have found previously that acute Rho kinase inhibition nearly normalizes PAH in chronically hypoxic rats that have no occlusive neointimal lesions. Here we examined whether Rho kinase-mediated vasoconstriction was also important in a rat model of severe occlusive PAH. Adult rats were exposed to chronic hypoxia (Ϸ10% O 2 ) after subcutaneous injection of the vascular endothelial growth factor receptor inhibitor SUGEN 5416. Hemodynamic measurements were made in anesthetized rats after 2 weeks of hypoxia (early group) and 3 weeks of hypoxia plus 2 weeks of normoxia (late group). Both groups developed PAH, with greater severity in the late group. In the early group, intravenous fasudil was more effective than intravenous bradykinin, inhaled NO, or intravenous iloprost in reducing right ventricular systolic pressure. Despite more occlusive vascular lesions, fasudil also markedly reduced right ventricular systolic pressure in late-stage rats. Blood-perfused lungs from late-stage rats showed spontaneous vasoconstriction, which was reversed partially by the endothelin A receptor blocker BQ123 and completely by fasudil or Y-27632. Phosphorylation of MYPT1, a downstream target of Rho kinase, was increased in lungs from both groups of rats, and fasudil (intravenous) reversed the increased phosphorylation in the late group. Thus, in addition to structural occlusion, Rho kinase-mediated vasoconstriction is an important component of severe PAH in SUGEN 5416/hypoxia-exposed rats, and PAH can be significantly reduced in the setting of a severely remodeled lung circulation if an unconventional vasodilator is used. S evere pulmonary arterial hypertension (PAH) in adult patients is characterized by progressive narrowing/occlusion of small pulmonary arteries, which frequently leads to right heart failure and death. 1,2 Factors thought to contribute to the formation of pulmonary vascular lesions include sustained vasoconstriction, vascular remodeling, and in situ thrombosis. However, it is now widely believed that fixed obstruction resulting from vascular remodeling is the major cause of the elevated vascular resistance in severe, progressive PAH. 3,4 Large clinical studies show that only Ϸ13% of adult PAH patients have a significant decrease in pulmonary artery pressure during acute vasodilator testing at the time of diagnosis, 5 suggesting a major fixed structural but minor reversible vasoconstrictor component in this group of pulmonary vascular diseases.Reeves et al proposed in 1986 that over time in PAH, the hypertensive component attributable to vasoconstriction decreases, whereas that attributable to fixed obstruction increases. 6 This concept cannot be tested clinically, because it is essentially impossible to obtain serial hemodynamic data and matched lung tissue samples for thorough assessment of the lung vascular morphology. At best, a single lung specimen becom...

SUMMARY. To characterize the hemodynamic factors that regulate stroke volume during upright exercise in normal man, 24 asymptomatic male volunteers were evaluated by simultaneous right heart catheterization, radionuclide angiography, and expired gas analysis during staged upright bicycle exercise to exhaustion. From rest to peak exercise, oxygen consumption increased from 0.33 to 2.55 liters/min (7.7-fold), cardiac index increased from 3.0 to 9.7 liters/min per m 2 (3.2-fold), and arteriovenous oxygen difference increased from 5.8 to 14.1 vol% (2.5-fold). The increase in cardiac index resulted from an increase in heart rate from 73 to 167 beats/min (2.5-fold), and an increase in left ventricular stroke volume index from 41 to 58 ml/m 2 (1.4-fold). During low levels of exercise, there was a linear increase in cardiac index due to an increase in both heart rate and stroke volume index; stroke volume index increased as a result of an increase in left ventricular filling pressure and end-diastolic volume index and, to a much smaller extent, a decrease in end-systolic volume index. During high levels of exercise, further increases in cardiac index resulted entirely from an increase in heart rate, since stroke volume index increased no further. Left ventricular end-diastolic volume index decreased despite a linear increase in pulmonary artery wedge pressure; stroke volume index was maintained by a further decrease in endsystolic volume index. The degree to which stroke volume index increased during exercise in individuals correlated with the change in end-diastolic volume index (r = 0.66) but not with the change in end-systolic volume index (r = 0.07). Thus, the mechanism by which left ventricular stroke volume increases during upright exercise in man is dependent upon the changing relationship between heart rate, left ventricular filling, and left ventricular contractility. At low levels of exertion, an increase in left ventricular filling pressure and end-diastolic volume are important determinants of the stroke volume response through the Starling mechanism. At high levels of exertion, the exercise tachycardia is accompanied by a decrease in end-diastolic volume despite a progressive increase in filling pressure, so that stroke volume must be maintained by a decrease in end-systolic volume. (Cire Res 58: 281-291, 1986)

RhoA GTPase mediates a variety of cellular responses, including activation of the contractile apparatus, growth, and gene expression. Acute hypoxia activates RhoA and, in turn, its downstream effector, Rho-kinase, and previous studies in rats have suggested a role for Rho/Rho-kinase signaling in both acute and chronically hypoxic pulmonary vasoconstriction. We therefore hypothesized that activation of Rho/Rho-kinase in the pulmonary circulation of mice contributes to acute hypoxic pulmonary vasoconstriction and chronic hypoxia-induced pulmonary hypertension and vascular remodeling. In isolated, salt solution-perfused mouse lungs, acute administration of the Rho-kinase inhibitor Y-27632 (1 x 10(-5) M) attenuated hypoxic vasoconstriction as well as that due to angiotensin II and KCl. Chronic treatment with Y-27632 (30 mg x kg(-1) x day(-1)) via subcutaneous osmotic pump decreased right ventricular systolic pressure, right ventricular hypertrophy, and neomuscularization of the distal pulmonary vasculature in mice exposed to hypobaric hypoxia for 14 days. Analysis of a small number of proximal pulmonary arteries suggested that Y-27632 treatment reduced the level of phospho-CPI-17, a Rho-kinase target, in hypoxic lungs. We also found that endothelial nitric oxide synthase protein in hypoxic lungs was augmented by Y-27632, suggesting that enhanced nitric oxide production might have played a role in the Y-27632-induced attenuation of chronically hypoxic pulmonary hypertension. In conclusion, Rho/Rho-kinase activation is important in the effects of both acute and chronic hypoxia on the pulmonary circulation of mice, possibly by contributing to both vasoconstriction and vascular remodeling.

Acute hypoxic pulmonary vasoconstriction (HPV) and the development of chronic hypoxic pulmonary hypertension (PHTN) are cardinal features of the pulmonary circulation that differentiate this vascular bed from the systemic circulation. Nitric oxide (NO) produced by pulmonary vascular endothelium is thought to modulate pulmonary vascular responses to a variety of vasoconstrictor stimuli, including hypoxia (1-8). However, despite intensive investigation over the past decade, the role of endotheliumderived nitric oxide (EDNO) in modulating tone and structural remodeling of the chronically hypoxic pulmonary circulation remains controversial (9-13).Simultaneous pharmacologic inhibition of all three isoforms of nitric oxide synthase (NOS) results in acutely increased pulmonary vascular resistance and augmented HPV (1,(14)(15). However, chronic NOS inhibition does not result in PHTN and does not augment the development of hypoxic PHTN (16). These results present a paradox: If EDNO modulates acute HPV, why is pharmacologic inhibition of NOS not associated with either normoxic PHTN or accentuated chronic hypoxic PHTN? One possibility is that HPV is redundantly modulated, and the loss of endothelial nitric oxide synthase (eNOS)-derived NO alone is not sufficient to produce PHTN. Alternatively, the experimental approaches taken in the past to test this question may have been inadequate because of nonspecific effects of pharmacologic inhibitors of NOS, difficulty maintaining NOS inhibition, or confounding effects of simultaneous inhibition of all three isoforms of NOS.Mice with targeted disruption of eNOS (eNOS -/-mice) have recently been constructed and the vascular phenotype explored (17,18). Systemic hypertension and augmented structural remodeling after vascular injury have been reported (19,20). Steudel et al. (21) investigated the pulmonary vascular phenotype of eNOS -/-mice, finding increased pulmonary vascular resistance, but only minimal PHTN, and no evidence of pulmonary vascular remodeling. More recently, this group also found enhanced chronic hypoxic PHTN in eNOS-null mice (22). These studies were limited, however, to mice exposed to severe hypoxia (FiO 2 = 11%) and studied under general anesthesia with hyperoxic (FiO 2 = 80%) mechanical ven- Acute hypoxic vasoconstriction and development of hypoxic pulmonary hypertension (PHTN) are unique properties of the pulmonary circulation. The pulmonary endothelium produces vasoactive factors, including nitric oxide (NO), that modify these phenomena. We tested the hypothesis that NO produced by endothelial nitric oxide synthase (eNOS) modulates pulmonary vascular responses to hypoxia using mice with targeted disruption of the eNOS gene (eNOS -/-). Marked PHTN was found in eNOS -/-mice raised in mild hypoxia when compared with either controls or eNOS -/-mice raised in conditions simulating sea level. We found an approximate twofold increase in partially and fully muscularized distal pulmonary arteries in eNOS -/-mice compared with controls. Consistent with vasoconstriction...

We have found in chronically hypoxic rats that acute intravenous administration of the Rho kinase inhibitor Y-27632 nearly normalizes the pulmonary hypertension (PH) but has no pulmonary vascular selectivity. In this study, we tested if oral or inhaled Y-27632 would be an effective and selective pulmonary vasodilator in hypoxic PH. Although acute oral Y-27632 caused a marked and sustained decrease in mean pulmonary arterial pressure (MPAP), it also decreased mean systemic arterial pressure (MSAP). In contrast, 5 minutes of inhaled Y-27632 decreased MPAP without reducing MSAP. The hypotensive effect of inhaled Y-27632 on hypoxic PH was greater than that of inhaled nitric oxide, and the effect lasted for at least 5 hours. Inhaled fasudil, another Rho kinase inhibitor, caused selective MPAP reductions in monocrotaline-induced PH and in spontaneous PH in fawn-hooded rats, as well as in chronically hypoxic rats. These results suggested that inhaled Y-27632 was more effective than inhaled nitric oxide as a selective pulmonary vasodilator in hypoxic PH, and that Rho kinase-mediated vasoconstriction was also involved in the other models of PH. Inhaled Rho kinase inhibitors might be useful for acute vasodilator testing in patients with PH, and future work should evaluate their efficacy in the long-term treatment of PH.